Global Cancer Immunotherapy Market: $100+ Billion Analysis & Forecast 2020-2023 -

DUBLIN--()--The "Global Cancer Immunotherapy Market Analysis & Forecast to 2023" report has been added to's offering

Within the cancer therapeutics space, which today is worth over $100 billion globally, immunotherapeutic drugs have gained worldwide acceptance.

This is because they are targeted therapeutics that have high specificity for cancer cells. Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $75 billion in 2019 alone and are forecast to surpass $115 billion in 2023.

This report describes the evolution of such a huge market in 20 chapters supported by:

  • An overview of cancer immunotherapy that includes: monoclonal antibodies, ADC's, cancer vaccines and non-specific cancer immunotherapies and CAR T therapies.
  • Focus on current trends in cancer immunotherapies that include: anti-PD-1 and anti-PDL1 drugs, Dendritic cell vaccines, T-cell therapies, and cancer vaccines.
  • Insight into the challenges faced by drug developers, particularly about the success vs. failure ratios in developing cancer immunotherapy drugs.
  • Descriptions of more than 23 cancer immunotherapeutics approved and used as targeted drugs
  • Insight into the various immunotherapeutics available for specific cancer types.
  • Description and data for the prevalence of cancer types that are addressed by cancer immunotherapeutics.
  • Overall global cancer therapeutics market, leading market players and the best selling cancer drugs.
  • Detailed account of the market for cancer immunotherapeutics by geography, indication, company, and individual drugs.
  • Profiles, marketed products, and products in the pipeline of 79 companies that are located globally
  • A summary table to identify the category of immunotherapy drugs offered by the 79 companies.
  • A specific chapter on the CAR-T industry detailing manufacturing, regulations, and pricing

Key Topics Covered:

1.0 Executive Summary

1.1 Objectives of Report

1.2 Key Questions Answered in this Report

1.3 Data Sources and Methodology

2.0 Cancer Immunotherapy: An Overview

2.1 Human Immune System

2.2 Types of Cancer Immunotherapy

2.3 Monoclonal Antibodies (Mabs) to Treat Cancer

2.4 Types of Monoclonal Antibodies (MAbs)

2.5 Cancer Vaccines

2.6 Non-Specific Cancer Immunotherapies and Adjuvants

2.7 New Frontiers in Cancer Immunotherapy Research

2.8 Cancer Immunotherapy: Timeline of Progress

3.0 Current Status of Cancer Immunotherapy: An Overview

3.1 Programmed Death (PD-1) Inhibitors

3.2 Keytruda (Pembrolizumab, MK-3475)

3.3 Tecentriq from Roche

3.4 Pidilizumab from CureTech

3.5 An Overview of Anti-PD-1 Clinical Development

3.6 Studies with Yervoy (Ipilimumab)

3.7 Studies with Tremelimumab

3.8 KAHR-102

3.9 TIM3 Antibody

3.10 BMS-989016

3.11 ImmuTune IMP701 and ImmuFact IMP321

3.12 Dendritic Cell Therapies

3.13 Chimeric Antigen Receptor T-Cells (CAR-T) Therapies

3.14 Cancer Vaccines

3.15 Miscellaneous Immunotherapies

3.16 Most Valuable R&D Projects in Cancer Immunotherapy

4.0 Challenges in Cancer Medicine Research: An Overview

4.1 Years of Failures and Emerging Successes in Melanoma Medicine Research

4.2 A New Era for Lung Cancer Medicines

4.3 Ray of Hope for Brain Cancer Patients

5.0 Cancer Immunotherapeutic Products: An Overview

5.1 I-Labelled Tositumomab (Bexxar)

5.2 Y-Labelled Ibritumomab (Zevalin)

5.3 Alemtuzumab (Campath)

5.4 Adotrastuzumab Emtansine (Kadcyla)

5.5 Bacillus Calmette-Guerin (BCG)

5.6 Bevacizumab (Avastin)

5.7 Brentuximab Vedotin (Adcetris)

5.8 Cetuximab (Erbitux)

5.9 Cervarix

5.10 Denileukin Diftitox (Ontak)

5.11 Gardasil

5.12 Gemtuzumab (Mylotarg)

5.13 Hepatitis B Vaccine

5.14 Interferon Alfa (IFN-alfa)

5.15 Interleukin-2 (IL-2)

5.16 Ipilimumab (Yervoy)

5.17 Ofatumumab (Arzerra)

5.18 Panitumumab (Vectibix)

5.19 Pembrolizumab (Keytruda)

5.20 Rituximab (Mabthera)

5.21 Sargramostim (Leukine)

5.22 Sipuleucel-T (Provenge)

5.23 Trastuzumab (Herceptin)

6.0 Available Immunotherapies for Cancer by Disease Type: An Overview

6.1 Melanoma Skin Cancer and Immunotherapy

6.2 Breast Cancer and Immunotherapy

6.3 Immunotherapy for Prostate Cancer

6.4 Immunotherapy for Lung Cancer

6.5 Immunotherapy for Colorectal Cancer

6.6 Immunotherapies in Development for Lymphoma

6.7 Immunotherapy for Kidney Cancer

6.8 Dominance of MAbs and Vaccines in Cancer Clinical Research

6.9 Oncology Biologics Losing Patent Protection

7.0 Cancer Incidence and Mortality: An Overview

7.1 Global Economic Burden of Cancer

7.2 Global Burden of Cancer

7.3 Top Five Most Frequent Cancers, Globally

7.4 Cancer Deaths in Women

7.5 Prevalence and Mortality for Cancer Types Addressed by Immunotherapy

8.0 Global Oncology Market Analysis and Forecast to 2023

8.1 Global Oncology Market Geographical Analysis and Forecast to 2023

8.2 Top Companies in Oncology Drug Sales

8.3 FDA approved oncology drugs to 2019

8.4 Top Oncology Drug Market Forecast to 2023

8.5 Global Oncology Therapeutics Market by Cancer Type

9.0 Market for Cancer Immunotherapy

9.1 Key Drivers

9.2 Global Market for Cancer Immunotherapeutics by Geography

9.3 Global Market for Cancer Immunotherapy by Product Class

9.4 Global Market for Immunotherapy Drugs by Cancer Type

9.5 Global Market for Monoclonal Antibodies for Cancer by Type

9.6 Global Market and Forecast for Cancer Vaccines

9.7 Global Market for Non-Specific Cancer Immunotherapeutics

10.0 Company Profiles

10.1 Ablynx NV

10.2 Activartis Biotech GmbH

10.3 Advaxis Inc

10.4 Aduro BioTech Inc

10.5 Agenus Inc

10.6 AlphaVax Inc

10.7 A. Menarini Industrie Farmaceutiche Riunite Srl

10.8 Amgen Inc

10.9 Antigen Express Inc

10.10 Argos Therapeutics Inc

10.11 Bavarian Nordic A/S

10.12 Bellicum Pharmaceuticals Inc

10.13 Biogen Idec Inc

10.14 Biovest International Inc

10.15 Bristol-Myers Squibb Company

10.16 Cellectis

10.17 Cellerant Therapeutics Inc

10.18 Celldex Therapeutics

10.19 CEL-SCI Corp.

10.20 CureTech Ltd.

10.21 Delta-Vir GmbH

10.22 Dendreon Corp.

10.23 DenDrit Biotech USA

10.24 DNAtrix Inc

10.25 Eli Lilly and Co.

10.26 EMD Serono Inc

10.27 Etubics Corp.

10.28 Galena Biopharma Inc

10.29 Genentech Inc

10.30 Genmab AS

10.31 GlaxoSmithKline

10.32 Gliknik Inc

10.33 GlobeImmune Inc

10.34 Heat Biologics Inc

10.35 Immatics Biotechnologies GmbH

10.36 ImmunoCellular Therapeutics Ltd.

10.37 Immunocore Ltd.

10.38 ImmunoFrontier Inc

10.39 ImmunoGen Inc

10.40 Immunomedics Inc

10.41 Immunotope Inc

10.42 Immunovaccine Inc

10.43 Inovio Pharmaceuticals Inc

10.44 Janssen Biotech Inc

10.45 Juno Therapeutics Inc

10.46 Kite Pharma Inc

10.47 MabVax Therapeutics Holdings Inc

10.48 MedImmune LLC

10.49 Merck & Co., Inc

10.50 Merrimack Pharmaceuticals Inc

10.51 Morphotek Inc

10.52 NewLink Genetics Corp.

10.53 Northwest Biotherapeutics Inc

10.54 NovaRx Corp.

10.55 OncoPep Inc

10.56 Oncothyreon Inc

10.57 OSE Pharma SA

10.58 Oxford BioTherapeutics Ltd.

10.59 Pique Therapeutics

10.60 Polynoma LLC

10.61 Prima BioMed Ltd.

10.62 Progenics Pharmaceuticals Inc

10.63 Regen Biopharma Inc

10.64 Roche Holdings Inc

10.65 Seattle Genetics Inc

10.66 Sorrento Therapeutics Inc

10.67 Spectrum Pharmaceuticals Inc

10.68 Synthon Pharmaceuticals Inc

10.69 TapImmune Inc

10.70 ThioLogics Ltd.

10.71 Transgene SA

10.72 TVAX Biomedical Inc

10.73 Vaccinogen Inc

10.74 Viventia Biotechnologies Inc

10.75 Wilex AG

10.76 Ziopharm Oncology Inc

11.0 Cancer Immunotherapy Market Participants by Product Segment

12.0 CAR T Therapy

12.1 Challenges Relating to Chimeric Antigen Receptor T Cells in Immunotherapy

13.0 Regulations Pertaining to Immunotherapy Regulation in the USA

13.1 Center for Biologics Evaluation and Research (CBER)

14.0 Regulations for Immunotherapy in Japan

14.1 PMDA and Immunotherapy

15.0 European Regulation and Immunotherapeutics

15.1 Introduction

15.2 Challenges for Immunotherapy in EMEA

15.3 Challenges Relating to Biomarkers in Immunotherapy

15.4 Challenges Relating to Chimeric Antigen Receptor T Cells in Immunotherapy

15.5 Estimating Optimal Cut-Off Parameters

15.6 EU-Approved Immunotherapies in Melanoma

15.7 Key Contacts Within EMA for Immunotherapeutics

16.0 Manufacturing of Immunotherapies

16.1 Introduction

16.2 Generation of CAR-Modified T Cells

16.3 Manufacturing Devices and Instruments Required for Immunotherapy Production

16.4 Good Manufacturing Procedure (GMP) for Immunotherapy

16.5 Case Study Production of Lentivirus Induced Dendritic Cells under GMP Conditions

16.6 Quality Control

16.7 Regulatory Affairs

16.8 Key Challenges in Manufacturing

17.0 Supply Chain & Logistics

17.1 Introduction

17.2 Case Study: Juno Therapeutics

18.0 Pricing & Cost Analysis

18.1 Introduction

18.2 CAR T Therapy Market Evaluation

19.0 Current Deals Within the CAR T Market

20.0 CAR T Therapy Company Case Studies

20.1 Juno Therapeutics

20.2 Kite Pharma

20.3 Cellectis

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900